View source for 6oiu


==X-ray crystal structure of the ectodomain of the Toxoplasma gondii ME49 Aminopeptidase N (TGME49_224350)==
<StructureSection load='6oiu' size='340' side='right'caption='[[6oiu]], [[Resolution|resolution]] 2.20&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[6oiu]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Toxoplasma_gondii_ME49 Toxoplasma gondii ME49]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6OIU OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6OIU FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.2&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6oiu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6oiu OCA], [https://pdbe.org/6oiu PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6oiu RCSB], [https://www.ebi.ac.uk/pdbsum/6oiu PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6oiu ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/S8G5K8_TOXGM S8G5K8_TOXGM] 
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Toxoplasmosis is a parasitic disease caused by infection with Toxoplasma gondii that currently has few therapeutic options. The M1 aminopeptidase enzymes have been shown to be attractive targets for anti-parasitic agents and / or vaccine candidates, suggesting potential to re-purpose inhibitors between parasite M1 aminopeptidase targets. The M1 aminopeptidase TgAPN2 has been suggested to be a potential new drug target for toxoplasmosis. Here we investigate the structure and function of TgAPN2, a homolog of the antimalarial drug target PfA-M1, and evaluate the capacity to use inhibitors that target PfA-M1 against TgAPN2. The results show that despite a similar overall fold, the TgAPN2 has a unique substrate specificity and inhibition profile. Sequence and structure differences are investigated and show how comparative structure-activity relationships may provide a route to obtaining potent inhibitors of TgAPN2.

X-ray crystal structure and specificity of the Toxoplasma gondii ME49 TgAPN2.,Marijanovic EM, Weronika Swiderka K, Andersen J, Aschenbrenner JC, Webb CT, Drag M, Drinkwater N, McGowan S Biochem J. 2020 Sep 14. pii: 226405. doi: 10.1042/BCJ20200569. PMID:32926129<ref>PMID:32926129</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 6oiu" style="background-color:#fffaf0;"></div>

==See Also==
*[[Aminopeptidase 3D structures|Aminopeptidase 3D structures]]
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Large Structures]]
[[Category: Toxoplasma gondii ME49]]
[[Category: Drinkwater N]]
[[Category: McGowan S]]